Guardant Health, Inc. (NASDAQ:GH) Short Interest Update

Guardant Health, Inc. (NASDAQ:GH) was the recipient of a significant increase in short interest in February. As of February 15th, there was short interest totalling 7,840,000 shares, an increase of 35.9% from the January 31st total of 5,770,000 shares. Based on an average trading volume of 2,130,000 shares, the days-to-cover ratio is currently 3.7 days.

Insider Activity

In related news, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the transaction, the director now owns 2,676 shares of the company’s stock, valued at approximately $93,660. This trade represents a 46.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 2,668 shares of company stock worth $95,208 over the last quarter. 5.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Guardant Health

Institutional investors have recently modified their holdings of the business. JNBA Financial Advisors purchased a new stake in Guardant Health during the 3rd quarter worth about $26,000. R Squared Ltd bought a new stake in shares of Guardant Health during the fourth quarter valued at about $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of Guardant Health in the third quarter worth about $34,000. SBI Securities Co. Ltd. bought a new position in shares of Guardant Health in the fourth quarter valued at approximately $43,000. Finally, Kimelman & Baird LLC bought a new position in shares of Guardant Health in the fourth quarter valued at approximately $58,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GH. Scotiabank raised their target price on Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Monday, February 24th. The Goldman Sachs Group raised their price objective on Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Canaccord Genuity Group upped their target price on shares of Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. Stifel Nicolaus increased their target price on shares of Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a report on Friday, February 21st. Finally, Barclays initiated coverage on shares of Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target on the stock. Nineteen analysts have rated the stock with a buy rating, Based on data from MarketBeat, Guardant Health has an average rating of “Buy” and a consensus target price of $48.21.

Guardant Health Price Performance

NASDAQ:GH opened at $40.74 on Tuesday. Guardant Health has a 1 year low of $15.81 and a 1 year high of $50.89. The business has a fifty day simple moving average of $41.09 and a two-hundred day simple moving average of $32.01. The company has a market capitalization of $5.03 billion, a P/E ratio of -11.44 and a beta of 1.32.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The firm had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, analysts anticipate that Guardant Health will post -2.9 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.